公司产品苓桂术甘汤颗粒、一贯煎颗粒和子公司产品多索茶碱片均列入《国家医保目录（2025年）》； 公司独家品种痰热清胶囊继续被纳入《国家医保目录（2025年）》，医保支付标准为4.09元/（0.4g/ 粒），协议有效期为2026年1月1日至2027年12月31日。公司子公司产品复方罗布麻片、斑秃丸调出《国 家医保目录（2025年）》，截止目前上述产品调出医保目录对公司经营业绩无实质影响。除上述调整 外，公司其他产品纳入《国家医保目录（2025年）》的情况与《国家医保目录（2024年）》保持不变。 格隆汇12月8日丨上海凯宝(300039.SZ)公布，公司及全资子公司上海凯宝新谊（新乡）药业有限公司 （简称"子公司"、"新谊药业"）共有92个药品纳入国家医保目录，其中甲类50个，乙类42个。主要涉及 独家品种3个(公司产品痰热清注射液、痰热清胶囊，子公司产品芪参胶囊)，独家剂型1个（公司产品多 索茶碱胶囊）等继续进入《国家医保目录（2025年）》。 ...

格隆汇12月8日丨上海凯宝(300039.SZ)公布，公司及全资子公司上海凯宝新谊（新乡）药业有限公司 （简称"子公司"、"新谊药业"）共有92个药品纳入国家医保目录，其中甲类50个，乙类42个。主要涉及 独家品种3个(公司产品痰热清注射液、痰热清胶囊，子公司产品芪参胶囊)，独家剂型1个（公司产品多 索茶碱胶囊）等继续进入《国家医保目录（2025年）》。 公司产品苓桂术甘汤颗粒、一贯煎颗粒和子公司产品多索茶碱片均列入《国家医保目录（2025年）》； 公司独家品种痰热清胶囊继续被纳入《国家医保目录（2025年）》，医保支付标准为4.09元/（0.4g/ 粒），协议有效期为2026年1月1日至2027年12月31日。公司子公司产品复方罗布麻片、斑秃丸调出《国 家医保目录（2025年）》，截止目前上述产品调出医保目录对公司经营业绩无实质影响。除上述调整 外，公司其他产品纳入《国家医保目录（2025年）》的情况与《国家医保目录（2024年）》保持不变。 ...

Company Announcements - *ST Zhengping has completed the stock suspension review and will resume trading on November 12, confirming normal production and operation without significant changes [1] - Upwind New Materials is in the product development stage for its embodied intelligent robot business, which has not yet achieved mass production or revenue generation [2] - Shannon Chip Innovation's fourth largest shareholder, Shenzhen Xinlianpu, has pledged 1.27 million shares for financing purposes [3] - Qing Shui Yuan's phosphorus trichloride products are primarily used in the production of water treatment agents [4] - Midea Group announced a cash dividend plan of 5 yuan per 10 shares, totaling 3.448 billion yuan, with the record date on November 17 [4] - Huiyuan Communication is planning a change of control, leading to a stock suspension starting November 12 [5] - Shen Gong Co. has clarified that some research reports on its performance forecasts represent only analysts' personal views [6] - World is developing diamond micro-drills for PCB processing, which are still in the R&D phase [6] - Haike New Source has signed an agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent [7] - Tongxing Technology plans to invest 3.2 billion yuan in a project to produce 100,000 tons of sodium battery cathode materials and 6 GWh battery cells [8] Investments & Contracts - Zhongjin Irradiation is investing 200 million yuan to build an electronic accelerator intelligent manufacturing project [10] - Hongri Da is collaborating with Te Du Technology and Hongke Tongchuang to establish a joint venture for semiconductor packaging [10] Shareholding Changes - Jian Kai Technology's controlling shareholder Xuanzhao plans to transfer 3% of its shares through a pricing inquiry [12] - Yue Wannianqing's shareholder Hehe Investment intends to reduce its stake by up to 3% [14] Financing & Capital Increase - Weiteng Electric plans to raise up to 300 million yuan through a private placement for various manufacturing projects [22] Other Developments - Zhifei Biological has received approval for clinical trials of a vaccine for adolescents and adults [23] - Shanghai Kaibao has obtained approval for clinical trials of a drug for acute ischemic stroke [24]

Core Viewpoint - The company, Anglikang (002940.SZ), has received approval from the National Medical Products Administration for its drug, Doxofylline Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved Doxofylline Tablets are available in dosages of 0.2g and 0.4g [1] - Doxofylline Tablets are indicated for bronchial asthma, asthmatic chronic bronchitis, and other respiratory difficulties caused by bronchospasm [1]

Overview - The market for Doxofylline tablets in China is steadily growing, driven by a large population of asthma patients, with sales expected to reach 125 million yuan in 2024, representing a year-on-year growth of 4.17% [1][8] - Public medical institutions account for over 90% of the sales, and the aging population is expected to further increase demand for Doxofylline tablets [1][8] Industry Chain - The upstream of the Doxofylline tablet industry includes raw materials, excipients, packaging materials, and pharmaceutical equipment; the midstream consists of production enterprises; and the downstream includes public medical institutions, physical pharmacies, e-commerce channels, and end consumers [4][5] Market Demand - The demand for Doxofylline tablets is significantly influenced by the procurement needs of public medical institutions, which are the primary sales channel due to the prescription nature of the drug [6] - As of the end of 2024, the number of medical institutions in China is projected to reach 1.092 million, a year-on-year increase of 2.0%, which will further expand the demand for Doxofylline tablets [6] Patient Demographics - The number of asthma patients in China is expected to reach 72.4 million in 2024, with a year-on-year growth of 4.32%, contributing to the increasing clinical demand for Doxofylline tablets [8] Competitive Landscape - The Doxofylline tablet market in China features both international companies and domestic firms, with local companies dominating the market. The competitive landscape is expected to evolve due to regulatory policies and procurement reforms [9][10] - Key domestic players include Fuan Pharmaceutical and Zhejiang Anglikang Pharmaceutical, with Fuan Pharmaceutical reporting a total revenue of 2.391 billion yuan and a gross profit margin of 52.96% in 2024 [10][11] Future Trends - The demand for Doxofylline tablets is anticipated to grow significantly in grassroots medical institutions as healthcare policies advance, leading to a downward trend in treatment accessibility [11] - Continuous implementation of volume-based procurement policies will encourage companies to enhance production efficiency and cost control, potentially increasing market concentration and optimizing the competitive landscape [11]

Core Viewpoint - Shanghai Kaibao reported strong financial performance in the first half of 2025, with significant revenue and profit growth, alongside advancements in research and product development [1] Financial Performance - The company achieved operating revenue of 605 million yuan in the first half of 2025, with a net profit attributable to shareholders of 122 million yuan [1] - The net cash flow from operating activities was 160 million yuan, reflecting a year-on-year increase of 21.92% [1] Research and Development - In the first half of 2025, the company invested 54.41 million yuan in research and development [1] - The company obtained one invention patent, one utility model patent, and one design patent during the reporting period [1] Product Development - The company received drug registration certificates for its classic formulations, including "Guo Yi Jian Granules" and "Ling Gui Zhu Gan Decoction Granules" [1] - The "Tan Re Qing Capsules" received approval for a new indication for use in the treatment of mild symptoms related to COVID-19, such as fever, cough, and sore throat [1] - Subsidiary Xinyi Pharmaceutical obtained registration approval for "Doxofylline Tablets," further enhancing the company's product line and market competitiveness [1] Company Overview - Shanghai Kaibao is primarily engaged in the research, production, and sales of modern traditional Chinese medicine [1] - The company is recognized as a national high-tech industrialization demonstration project base for modern traditional Chinese medicine and is among the first batch of traditional Chinese medicine enterprises to pass the new GMP certification [1] - The company has established three main product lines: respiratory products represented by "Tan Re Qing Injection/Capsules," cardiovascular products represented by "Qi Shen Capsules," and digestive products represented by "Sulfapyridine Series" [1]